Theefficacy of pertussis vaccines isa subject of longstanding controversy, with particular relevance today. The controversy dates back to the first trials of pertussis vaccines, which were carriedout duringthe 1930s. Thesewere criticized as biasedin favor of the vaccines because they were not randomized; vaccinated volunteers were comparedwith unvaccinated "nonvolunteers" [1, 2] . Although killed whole-cell pertussis vaccines were used increasingly in developedcountries duringthe 19408 and 19508 (they were first recommended for routine use in all children in the United Kingdom in 1957), conflicting accounts of their efficacy havecontinuedto be published. At least twice these reports have led to major policy changes. Evidence that the efficacy level of at least oneof the pertussis vaccines usedin the UnitedKingdom was only 20070 during the mid-1960s led to a changein the requiredcompositionand concentration of British standard vaccines in 1968 [3] . In the late 1970s pertussis vaccines were totally withdrawn from use in Sweden because of evidence that their efficacy had fallen virtually to zero [4, 5] . To what extent the variation in published estimates of pertussisvaccine efficacy is due to methodologic problemsin the studiesor to poorly understood biologic factors remains unclear.
The recent development of a new generation of acellular pertussis vaccines has been stimulated in large part by continued dissatisfaction with the efficacy and safety of traditional whole-cell vaccines [6, 7] . The demonstration that a new vaccine is in fact more effective than one or another traditional product maynot be easy, however, and efforts to assess new vaccines may well resurrect many of the problems confronted in studiesof the killedwholecellvaccines overthe past several decades. It is thus particularlyrelevant that wenowconsidercarefully the problems and controversies relatingto the protective efficacy of pertussis vaccines. Table 1 summarizes the results of all published reports known to us on the efficacy of whole-cell pertussis vaccines [1, 4, . Although the table maynot include allreports actually in print, it should at least be representative of methods and results found in the literature. The vaccine efficacies (VE) reported here are calculated according to the con-ventional defmition: VB = the percentage reduction in riskattributableto vaccination amongvaccinated individuals comparedwithsimilarly exposed unvaccinated individuals; that is, VE = (Rnv -R v)/Rnv = 1 -(Rv/Rnv), where Rnv is the risk of pertussis in the unvaccinated group and Rv is the risk of pertussis in the vaccinated group.
Estimation of Vaccine Efficacy
Some publications provide several different estimatesof vaccine efficacy, depending upon different case criteria, age groups, or vaccines. In some instancesthe vaccine efficacy given in table 1 wasnot calculated by the original authors but by us on the basis of data in the cited publication.
The table lists the studies in four groups according to the method used to derive vaccine efficacy: (1) controlled trials, in whichthere was random allocation of vaccine and placeboand active casedetection to provide estimates of Rv and Rnv; (2) cohort studies, basedon passive follow-up (i.e., notified cases) in populations in which vaccines were allocatedor accepted on a nonrandombasis; (3)secondary attack rate studies, involving active detectionof cases in households after the introduction of a primarycase; and (4) case-eontrol studies, in which vaccine efficacy wasestimatedthrough comparisonof the vaccination status of ascertained caseswiththat of a control group (often the general population). In this case the vaccine efficacy is derived as illustrated in table 2 [45] .
Thereisconsiderable variationin the estimates of vaccine efficacy presented in table 1 . That this variation cannot be explained by sampling error alone is evident fromthe 95070 confidence limitscalculated by standard methods for relative risk analysis [46] . We now discuss some of the other factors that may underlie these differences.
Protection Against What?
What does it mean to say that a vaccine protects againstpertussis? In surveying the literaturewenote that all publishedstudieshaveused clinicalcriteria and thus that reported statisticsreflectestimates of protection against clinical whooping cough rather than against infection with Bordetella pertussis. Looking deeper into this distinction, we find considerableevidence that conventional, killed, whole-cell pertussis vaccines are more effective in protecting against disease than in protecting against infection per see Several observations support or are consistent with this contention. 867 First,manyauthorshave reported that clinical pertussis isless severe in vaccinated than in unvaccinated individuals [1, 8, 12, 17, 18, 25, 26, 28, 47] . Indeed, we know of no study that has examined this question and failed to find this result, though the data aresometimes misleading if not brokendownbyage, as the most severe disease generally occursin infants too young to have been vaccinated.
Second, it iswidely accepted that the development of pertussisdisease represents a two-stage process: an initial colonization or infection stage during whichthe organisms attach to and proliferate on the respiratory tract mucosa, and an invasive or toxic stageassociated withcelldamageattributed to toxic productsof B pertussis [7, 48, 49] .Thesetwostages are mirroredin the immuneresponse, in that the infection stagestimulates productionof secretory IgA and the invasive stagestimulates productionof JgG. Of particular interestis the recentfindingbyseveral workers that the immune response to conventional pertussis vaccines involves predominantly IgG, with littleor no IgAcomponent [50, 51J, and that the titer of IgA antibodies to fimbrial hemagglutinin is inversely correlatedwith the persistence of B. pertussis infection in animal models [52] . This observation provides an immunologic rationale for the better protectionofferedby killed whole-ceU pertussis vaccines against the later morbidity-associated stages than againstthe initialcolonization stages of B. pertussis infection.
Third, pertussis epidemics appear cyclically, every 3 or 4 years in large populations (figure 1). The mechanism underlying thesecycles is reasonably well understood, being a dynamic interaction between the entry of susceptibles into the population (mainlyby births) and their depletion (mainlyby infection or vaccination and conversion into immunes) [53, 54] . As each epidemic is touched off by the attainment of a critical density of susceptibles in the population (called the epidemic thresholdand estimatedat 1' \.13.5 x 10 6 for Englandand Wales), the intervalbetweenepidemics should reflectthe rate of accumulation of susceptibles [55] . High birth rates and/or low uptake of immunizing vaccine should lead to a decrease in the intervalbetween epidemics. Conversely, low birth rates and/or high uptake of immunizing vaccine should lead to an increased interval. On the other hand, if the vaccine were to protect against disease much more than against infection, one wouldpredictthat the amplitudeof disease cycleswouldbe affectedbychanges in vaccine uptake by guest on April 6, 2011 cid.oxfordjournals.org Table 1 . Column entries apply to all cases in a given reference unless otherwise indicated.
• "Measure" codes refer to different methods of defining the population at risk or of selecting controls, as described elsewhere [45] : f = = case-control studies excluding past cases from control group.
t VB = vaccine efficacy, with 95070 confidence limits (CL) where calculation was possible. Where appropriate, a summary VE value is given (under a rule).
t Data are expressed as the number of doses in the vaccinated group vs. that in the comparison group; e.g., the entry "3vO" refers to three doses in the vaccinated group vs.
none in the comparison group. II "VE publ" indicates whether or not VB values were published in the paper cited. "Yes" in this column (inside quotation marks) indicates that the published VB differs from the age-standardized estimate given here.
# NS = not stated in original publication.
•• AHAs = area health authorities.
tt Index cases were bacteriologically positive.
tt See II" Controls were matched for school, age, and sex.
••• Controls were measles cases. 
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Implications of Ascertainment and Diagnostic Criteria
All published studies of pertussis vaccines have used clinical criteria to define pertussis. They have thus assessed protectionagainstdisease. Therehave been NOTE. The case-control method assumes that the selection of cases is independent of their vaccination status and that these cases can therefore be used to estimate the relative risk of pertussis among vaccinated and unvaccinated individuals. This estimate is obtained by comparison with the distribution of vaccination in a control group matched for age and other variables. VE = 1 -(AD/BC) [45] .
to a much greater degree than wouldthe frequency. This is in fact what has been observed in England and Wales over the past three decades [53] .
Fourth, the literature contains several reports of the isolation of B. pertussis from asymptomatic individualswith a history of vaccination [26, 56, 57] . considerable differences in the actual criteria used in different investigations, however, and thesedifferences have undoubtedlyaffectedthe numericalestimates of vaccine efficacy. The more important of these differences are described below.
The greaterthe clinical severity of cases accepted as pertussis, the higher should be (and have been) the estimates of vaccine efficacy. This relation is predicted bythe evidence already presented that vaccines are moreefficient in protecting againstdisease than against infection. Probablyforthisreason, casecontrolstudies based uponhospitalized patients yield highestimates of vaccine efficacy (e.g., >95070 inthree studiesof hospitalized patients in the United Kingdom [41, 43, 44] ). Similarly, clinically severe cases are moreliableto be bacteriologically positive than are mildcases (table 3) ,and it isconsistently reported that the protective efficacy of vaccine is higher against bacteriologically proven cases than against the total number of cases or against bacteriologicallynegative cases [17, 42] . Thisrelationwould also leadto overestimates of vaccine efficacy amongpassively notified cases if therewas a correlation between clinical severity and the probabilitythat a physician both recognizes and notifiesa case. It wouldnot be surprising to us if therewas indeedjust sucha correlation and if this situation had tended to raise estimates of vaccine efficacy in some cohort as well as case-control studies. [17] .
• The association of bacteriologic positivity with an increased number of paroxysmal coughs per day is highly significant for individuals who received three doses of diphtheria-tetanus (DT) vaccine and for both groups considered together (X 2 >11; P < .(05). This association is not significant for individuals who received three doses of diphtheria-tetanus-pertussis (DTP) vaccine. Note also the implication of greater clinical severity (i.e., a higher proportion with >10 paroxysms) among persons not vaccinated against pertussis (DT recipients) than among those vaccinated (DTP recipients).
If a physician's knowledge of vaccinationhistory influences the diagnosis, estimates of vaccine efficacywill be affected. In particular, if knowledge that a childhas received pertussisvaccine reduces the index of suspicion that an illness is in fact pertussis, vaccine efficacywillbe overestimated insofar as the observed risk of pertussis among vaccinees will be prejudicially reduced.It must be difficult for a physician to escape such a bias, in particular if he or shewasresponsible for the vaccination; a total avoidance of the bias wouldimply no faith in the protective properties of the vaccine. It is possiblethat this biashas influenced vaccine efficacy estimates derived in cohort and case-control studiesbased on notified disease. Studies of household secondary-attack rates are also subject to this bias unless the follow-up of household members isconducted withoutknowledge of vaccine status. None of the publishedhouseholdcontact studieshas mentionedstringentmeasures to avoid such a bias.
There is also an important potential diagnostic bias in the opposite direction, in that the inclusion of illnesses that are not in fact due to B. pertussis willtend to reducethe observed estimate of pertussis vaccine efficacy. It is shownin figure 2 (and the appendix at the conclusion of thisarticle) that if only PfTJo of the apparent pertussiscases among nonvac-
Implications of Distribution and Ascertainment of Vaccination
The calculationof vaccine efficacy assumes that the compared vaccinated and unvaccinated groups are equally exposed to infection. While this equal- 1.0 cinees are in fact due to B. pertussis, and if the incidence rate of the condition that is mistakenlydiagnosedas pertussis isnot affected bypertussis vaccine, then the observedvaccine efficacywill be approximatelyPfTJo of the "true value." This effect of nonspecific diagnoses is enhanced if the ascertainment (diagnostic sensitivity) of true cases is incomplete. Giventhe widely recognized difficulties in diagnosing pertussis [58] , it is likely that this bias has affected manystudies.It is an additional causefor the highervaccine efficacies reported in studies restricted to bacteriologically confirmed cases.
It is clear from this discussion that diagnostic and ascertainment criteria can affect the observed level of vaccine efficacyin different ways. The net effect of the differentbiaseson anystudy is in general difficult to assess. exposure conditioncan be assumed in a properlydesignedcontrolledtrial, it maynot be upheld in routine vaccination programsas investigated by cohort and case-control methods. (The special problemof exposure in secondary attackratestudies isdiscussed below.) Ifvaccine uptakewithincommunities is nonrandom, or nonuniform, and if groups withhighvaccine coverage are at low risk of exposure to infection, then studieswilloverestimate vaccine efficacy. If onegrantsthat vaccine coverage isliable to be nonhomogeneous in most humansocieties, therearetwo reasonsto supposea bias in the directionproposed here. First,it islikely that vaccine uptakewill be high in areas where overall medical services and hygiene are good. This pattern may be relevant to pertussis in that several authors havesuggested that the diseaseis severest in lessadvantaged socialclasses [38, 59] , amongwhomvaccine uptakeislow [19, 60] . Second, insofar as high rates of vaccination may impart some indirect protection (herd immunity) to others in a neighborhood,this indirecteffectwill be directed preferentially -if ironically -towards vaccinated individuals (in the same neighborhood) rather than unvaccinated individuals (inother neighborhoods).
On the other hand, the nonuniform distribution of vaccination in a population introduces the potential for a bias against the vaccine in studies based upon notified cases. If the tendency to notify is a correlate of good public-healthpracticeand hence is associated with high vaccine uptake, then there couldbe preferential reporting of cases in vaccinated individuals, leadingto an underestimate of vaccine protection.
A relatedproblemarises for cohort and case-control studies that depend on retrospective ascertainment of vaccination histories. Several studies have shown that parental recall or school records often disagree with the vaccinationhistory as recorded in the clinic where vaccinations were actuallygiven [61, 62] . Classificationerrors in vaccination status will in general tend to reduce estimates of vaccine efficacyunless thereis a biastowards misrepresenting vaccinatedpatientsas unvaccinated. Given problems in recordkeeping, there is probablya greatertendency for false-negative rather than false-positive recorded vaccinationhistories. Records will thus tend to underestimate vaccinations among cases and may inflate the vaccine efficacy observed in cohort studies that usevaccine uptakestatistics for the total population in estimating denominators (e.g., the study by
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Church [21] ). Case-control studies canin theoryovercomethis vaccination-ascertainment bias byusinga groupwithdisease not preventable by vaccination as controls [40] . If the control disease is itself preventablebyvaccination, however, vaccine efficacy will be overestimated sincesuch controls willtend to come from social groups with low vaccine uptake [43] .
Differences Between Vaccines
It is possible that some of the differences shownin table 1are attributable to differences in the composition and preparation of variousvaccines. This situation is most clearly evident in the results of the early trials carried out by the Medical Research Councilin the UnitedKingdom, duringwhich it was found that vaccines prepared by the Michigan protocolwere appreciably moreeffective than the others used [8] . Moreover, a significant difference was foundbetween twovaccines usedin the UnitedKingdom during the 1960s [24] . Unfortunately, in most investigations the vaccines usedeitherhave not been known or have not been specified.
It has been suggested that the fall in efficacy of pertussis vaccines in Sweden during the 1970s was due to a changein vaccine formulation at the beginning of the decade [4] .
Despite considerable caretaken bymanufacturers to standardize their products, some residual batch variation is to be expected. This variation may apply moreto pertussisthan to other commonlyused vaccines, particularlybecause the mouseprotection test used to standardizesuch vaccines is recognized to be lessprecise than might be wished [63] [64] [65] . Although there may well be some variation between different batches of vaccine prepared by the same manufacturer, we expect that this variation is not a major source of the differences evident in table 1.
Variations in Wild B. pertussis
Several different antigenic types of B. pertussis are known to coexist in most populations. These are traditionallydefinedin termsof threemajor surface antigens, often calledagglutinogens, found in combinations as strainsor "serotypes" 1-2, 1-2-3, and 1-3. There is some evidence for strainspecificity of vaccines. An increase in the proportion of strain 1-3 among circulating B. pertussis has been reported in several countries in past decades and has been attributed to widespread use of vaccines including in- NOTE. The schedules cited here were selected solely to illustrate variations between countries and over time; they are not intended to be representative of vaccination schedules in the world today. OPT = diphtheria-pertussis-tetanus.
• An interval of only one month between doses is recommended during epidemic periods. t Except for the Danish study, the intervals shown are those between the first and second doses. t Except for values expressed as ages, the intervals shown are those between the second and third doses.
sufficient or no strain 1-3 component [12, [66] [67] [68] [69] . The lowreported efficacyof certain British pertussis vaccines during the mid-l960s was attributed in large part to this factor [24] . Although this contention of strain specificity has not been accepted universally [70] , it wasconsidered sufficientlycompellingto warrant a changein composition (including the necessary inclusion of serotype 1-3 organisms)in Britishvaccines producedafter 1968 [3, 24] . Thereis evidence that the immuneresponse to the agglutinogen 2 component hasbeengreater than that to the agglutinogen 3 componentof several vaccines used in England and Wales [71, 72] .This difference mayexplainthe high proportion of strain 1-3 organisms in some well-vaccinated communities. In this context it is of interest that the predominant serotype of B pertussis in England shifted from 1-3 to 1-2 subsequent to the fall in vaccine uptake in the mid-1970s [73, 74] .Recent reports from Finland describe a situation opposite but complementary to that in Englandand Wales. In Finnishpertussis vaccines, agglutinogen 2 has proved less immunogenic than agglutinogen 3 and the vast majority of wild B. pertussis strains belong to the 1-2 serotype [75, 76] .Taken together, thesereports from Englandand Finland argue strongly in favor of some degree of strain specificity for whole-cell pertussis vaccines.
The selective forces that determine the relative frequencies of the differentserotypes of B pertussis in unvaccinated populations are inadequately understood, as is the extentof natural cross-protection imparted byand between theseserotypes. Whatever the selective forces are, they would be expected to vary overtimeand between different human populations; thus, they could be responsible for some of the observed differences in vaccine efficacy. What is more, the evidence that pertussisvaccines may in the past haveselected for strainsantigenically differentfrom those in the vaccines arguesfor continued monitoring of the efficacyof vaccines used in routine programs.
Doses and Schedules
The recommended pertussis vaccination schedule has varied between countries and over time, as is illustrated in table 4. These varyingschedules may well be responsible for some of the reported differences in vaccine efficacy (table 1) .
There is evidence that for a maximal protective response to pertussisvaccines, the first dose should not be given until a child is at least 1 month of age, presumablybecauseof interference from maternal antibody in the first month of life [65, 77] . Evidence also supports an inverse relation between vaccineinduced IgG response and cord blood titer [51] , but we have found no convincing data relating the age of initial vaccination to protection per se. Some studies on this topic have been seriously flawede.g.,children vaccinated at an early age at urban welfare clinics have been compared with rural children vaccinated at later ages [78] . Given that the severity of clinical pertussis is also inversely related to age, the decision as to the optimal age for initial vaccination willvary between populations and willchange in response to changes in the epidemiology ofB pertussis. The lower the risk of infection in the community (and in particular among young infants), the longer the initial vaccination may be delayed.
It is recognized that multiple doses of pertussis vaccines are required for an optimal immune response. A primary course of three doses, with intervals of 6-8 weeks between the first and second and 4-6 months between the second and third, is currently recommended in England and Wales. Although it was once believed that the final response was impaired if the interval between doses was too long, this is no longer thought to be true [79] . Few investigations have permitted estimates of the relative protection provided by one, two, or three doses of vaccine, but the few data available suggest a progressive increase in protection imparted by the three doses (table 5) . Although boosters at 18months and/or 5 years of age have been and are still recommended in some countries, we are aware of no data regarding their protective implications.
Duration of Protection
Pertussis has traditionally been considered a disease of children and was rarely diagnosed in adults before the introduction of vaccines. From this simple observation came the opinion that infection with the pertussis agent imparts lasting and solid protective immunity. We have thus been interested to note a number of recent publications on pertussis in adults [4, 80, 81] .Of course, these articles may reflect nothing more than the growth of the scientific literature in general. Alternatively, they may reflect merely a shift in the age distribution of pertussis cases and an increasing proportion of adult cases as the disease is effectively controlled among children. Agespecific notification data from England and Wales seem to support the latter interpretation ( figure 3 ). On the other hand, several authors have recently ex-
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pressed a concern that pertussis immunity may be only partial among adults, that they may carry repeated asymptomatic infections, and that such repeated infections may be necessary to maintain long-lasting protection against disease: [ These observations] suggest that young adults with waning immunity and mild illness are a major reservoir for transmission of pertussis to infants. [80] This suggests the possibility that persisting immunity in vaccinated populations depends on subclinical or mild infections to booster waning immunity in later years. [70] Before pertussis vaccination was introduced whooping cough in adults was very uncommon.... The good immunity in adults may have been due to repeated natural booster doses through exposure to the disease. [4] We think that serologic responses in asymptomatic persons represent a natural booster phenomenon continuously occurring in relatives of patients with pertussis and thus maintaining herd immunity. [82] The literature contains few data by which the du- [30] 11-to 20-y-old 100 50
Secondary attack 0-to 4-y-old 59 93 rate [56] '" Children were the ages listed in 1978. YEARS ration of vaccine-derived protection against pertussis can be assessed. A fewstudies giveantibody titers by age, but the implications of such data for protection are not yet known [50] . In general, controlled trials of pertussis vaccines have not included a follow-up period sufficiently long for a determination of whether vaccine-derived protection wanes with time. On the other hand, several case-control and cohort studies provide data for groups of various ages or with various intervals elapsed since vaccination. Overall, these results indicate either stable vaccine efficacy [17] or a slight decrease with time [21, 25, 26, 40] . Table 5 includes data from a cohort study in Hertfordshire that may suggest a slight fall in protection imparted by three doses with age and time since vaccination [21J. Figure 4 shows the results of a classical case-control study; the findings are suggestive of a fall in efficacy with age and hence with the interval since vaccination [40] . (The original report did not present data by age at vaccination, and the trend in figure  4 may be confounded by selective allocation of vaccine to children without a history of prior pertussis.) Such observations of falling vaccine efficacy with time need not necessarily represent waning immunity. It has been pointed out elsewhere [45J that calculated efficacy will fall over time if a vaccinegives constant but relative protection (i.e., it reduces risk in all vaccinees but renders none totally immune for life) and if the efficacy estimates are based either upon cohort-study incidence risks calculated with initial population denominators (as in table 5) or upon case-control studies in which the control group is selected without regard to a history of pertussis (as in figure 4 ).
Protection Under Conditions of Household Exposure
Vaccine efficacy estimates derived in studies of household secondary-attack rates have in general been slightly lower than those obtained by other methods (table 1) , despite the susceptibility of the former studies to diagnostic bias (as described earlier). The association of a low vaccine-efficacy rate with household contacts appears to be independent of diagnostic criteria: in a recent study by the Epidemiological Research Laboratory in the United Kingdom, the efficacy rate in the general population was found to be 1'\184070 and 1'\193070 for all cases and for bacteriologically proven cases, respectively, but only 1'\153070 and 1'\181070 for the same two case groups among household contacts (table 1) [17] . We may ask whether this finding reflects biologic mechanism or methodologic artifact.
If pertussis vaccinesdo indeed protect less wellun- [40] .
der conditions of household exposure than under other conditions, this pattern would suggest that vaccine-derived protection is dependent upon exposure level or challenge dose. Presumably, household exposureimpliesmore frequentchallenge with largerdosesof B. pertussis than wouldnormallyoccur outside the intimacy of a home environment. It should also be recognized that the secondary attack rate method involves the study of highly selected populations -family contacts of ascertained cases -and that for several reasons this selection may introduce biases. First, the method requires information on both vaccinated and unvaccinated household contacts.If vaccine uptake is nonrandom, such that most or all members of some households are vaccinated and most or all members of the other households are not vaccinated, then most or all of the vaccinated individuals in the study will be included because of a prior vaccine failure inthe household (i.e., the indexcase). Insofar as risk factors for vaccine failure-whether they be genetic, socioeconomic, or a reflection of the quality of the vaccine provider-are likely to be shared by members of a household, then the selection process involved in studies of secondary attack rates introduces a bias against the vaccine.
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Second, studies of cases in which B. pertussis is introduced into a household by a vaccinated individual maybe biased in favorof the vaccine. This statement is again based upon the assumption that vaccine uptake is nonrandom and thus that household contacts will in general share the vaccination statusof the index case. Insofarastheclinical severity of pertussisis likelyto be reducedin vaccinated individuals, the contacts of these individuals may be exposedto fewer bacillithan are the contacts of unvaccinated personswith the disease. This lower level of exposure should reducethe risk of infectionpreferentially amongvaccinated contactsas a groupand thereby increase the apparentefficacy of the vaccine. (Theoppositecould be arguedif severely ill patients were somehow isolated from other household members.)
Third, the greater the number of pertussis cases in a family, the greateristhe possibility that the family will be identified and included in a study. This ascertainment bias, favoring households with larger rather than smallernumbersof cases, is presumably against the vaccine since households in which the vaccine is working bestwouldbe selectively excluded from study. One wayto lessen this bias is to restrict the analysis to caseswith onset after the households have been identified and visited.
A detailed analysis of data from a large study of householdsecondary-attack ratesin England has revealed highervaccine efficacy whenpatientswith index caseshavenot been vaccinated (consistentwith the first point just discussed) and when retrospectivelyascertainedcases havebeen excluded (consistent with the second point) (P. E. M. Fine, J. A. Clarkson, and E. Miller, unpublished data).
Thereis a particularlyinteresting exception to the general ruleof lower vaccine efficacy associated with householdthan withextrahousehold exposure. A direct comparison wasmade between these situations in the context of the first trials by the British Medical Research Council; no difference in vaccine efficacywas found (table 1) [8] . One possibleexplanation for this observation is that strain 1-2 of B. pertussis predominatedat the time of these early trials, whereas the poor performance of vaccines under conditions of household exposurehas been observed in periodswhenstrain 1-3 predominated (e.g., as reported in [24] ). On the other hand, because these trials were based entirely upon prospective followup, the finding of similar levels of vaccine efficacy in instances of household and extrahousehold ex-posure may be interpreted as evidence that the low efficacy observed in some subsequent household studies reflects biases in the ascertainment of the households studied.
Age-Distribution Artifacts
Vaccine efficacy studies can be seriously in error if data are not analyzed separately for narrow age groups or are not otherwise standardized for age. An example of this error is shown in table 6, which presents data from a household secondary-attack rate study of the efficacy of pertussis vaccines [30] . The authors concluded that the overall rate of vaccine efficacy was 630/0, but a close examination shows that the efficacy was lower than this figure in the only two age groups permitting an estimate. Insofar as the proportion of persons completely vaccinated will generally increase with age and the actual risk of pertussis in either vaccinated or unvaccinated groups will generally decrease with age (if for no other reason than that older individuals are more liable to have acquired natural immunity), a failure to take age into account will usually lead to overestimates of vaccine efficacy. Age standardization of the data shown in table 6 (by means of the MantelHaenszel method [46] ) provides an overall efficacy estimate of 540/0, considerably lower than that derived by crude analysis. The literature contains several other obvious examples of this bias [27, 31] , and we suspect that many other studies presenting no data on age have been similarly affected.
Relation Between Serology and Protection
A serologic marker correlating strongly with protection would be useful for the measurement and monitoring of the efficacy of pertussis vaccines. Early investigations measured only agglutinin responses [71, 77, [83] [84] [85] , but more recent studies have examined IgG and IgA responses to other specific components of B pertussis [6, 50-52, 86, 87] . In general, seroconversion rates and titers increase with successivedoses of vaccine and are higher if the vaccination course is initiated after 3 months of age, presumably because of blocking by maternal antibody in a proportion of younger infants. NOTE. Data are from [30] .
• Three to five doses.
t The overall figure of 63010 for ages 0-20 y is an overestimate because an increase in the proportion of individuals vaccinated and a decrease in pertussis risk occur simultaneously with age.
ever, the observation that some children lacking agglutinins failed to contract clinical pertussis after exposure may indicate that the agglutinin response was itself a correlate of other "true" protective antibodies. The randomized controlled trials carried out by the British Medical Research Council in the 1950s included one acellular vaccine, "Pillemer's antigenic fraction," which was shown to provide a high level of protection against disease but to elicit almost no agglutinin response [64] . No recent investigators have succeeded in monitoring the serologic status of sufficient numbers of children to assess the protective implications of specific antibody types. On the other hand, the evidence that acellular vaccines containing few antigens may be protective against pertussis [7] may be a strong indication of which antibodies are important for protection. It may turn out that IgA antibodies to fimbrial hemagglutinin provide the main protection against infection and colonization, whereas IgG antibodies to lymphocytosis-promoting factor provide the main protection against systemic illness. The situation is still unclear.
Discussion
From this reviewit is obvious that assessment of the efficacy of pertussis vaccines is by no means simple. The variety of difficulties encountered is such that it is often impossible to assess whether the net effect in any particular study has been to underestimate or to overestimate vaccine efficacy. Fewpublications have provided sufficient data or have been sufficiently critical in their analyses to allow such an assessment. On the other hand, some authors (e.g., Noah [14] ) have been sufficiently aware of the problems to shy away from calculating vaccine efficacy and have been content to conclude only that the vaccine was providing statistically significant protection. In this context we admit having been less cautious than some of the original investigators in calculating the efficacy values cited in table 1. We believe that these calculations are justified, however,in that it is not enough merely to conclude that there is some protection -i.e., that a vaccine's efficacy is significantly greater than zero, as judged by statistical criteria. The fact that pertussis vaccineis generallygiven in combination with diphtheria and tetanus toxoids means a low marginal cost for the pertussis component and may justify the vaccine's use even at relativelylow efficacy.However,giventhe cost of providing any vaccine and the inevitable -if low -risk of adverse effects, one may question whether it is worthwhile for a government to administer a pertussis vaccine whose efficacy against recognizable clinical pertussis is, say, <50070 in a general population [89] .
Although we have delineated the problems involved in defining protective efficacy and in clarifying that against which the vaccinee is protected (death, severe disease, mild disease, or infection), we hesitate to insist upon one or another criterion. Each has its place. If the objective of a control program is merely to reduce morbidity, then a high rate of coverage with a vaccine protecting only against disease may be considered satisfactory. In contrast, if herd immunity is considered desirable or if eradication of pertussis is contemplated then the concern must be over whether or not the vaccine protects against infection. It might also be useful to consider a third form of protection: that against infectiousness or transmissibility. Insofar as conventional pertussis vaccines appear to be particularly effective in protecting against bacteriologically positive disease, they may indirectly reduce transmission in a population -even if they do not protect against infection per se -by reducing the potential for transmission by those vaccinated individuals who do become infected. We recognize that this argument appears inconsistent with the unchanged periodicity of pertussis epidemics in England and Wales in recent years (seethe above discussion, our earlier article [53] ,and the paper by Anderson and May [54] ). Indeed, this is one of the unresolved problems relating to the population effects of pertussis vaccines.
In attempts to assess the efficacy of a vaccine currently in use, it may be useful to look beyond the Fine and Clarkson confines of the data gathered in any particular study. If a vaccine is in widespread use, then we would expect its efficacy to be reflected in regional and national trends in pertussis morbidity. Thus, the dramatic decreases in notified pertussis cases both in the United States [90] and in England and Wales [3, 90] subsequent to the introduction of widespread vaccination have reasonably been cited as evidence of the effectiveness of the vaccines in use. Trends in pertussis-specific mortality may be less convincing evidence of vaccine effects, since the introduction of effective antibiotic therapy corresponded closely in time with the introduction of vaccines [91] . On the other hand, evidence that the efficacy of much of the pertussis vaccine used in England and Wales fell to only 20070 during the mid-1960s [24] and then rose to 80070 after the change in vaccine composition [17] is inconsistent with the notification trends illustrated in figure 1 . Indeed, we suspect that the low efficacy values were in part due to the secondary attack rate methods used to derive the estimates.
In this context it is appropriate to note that several authors have recently recommended use of the household secondary-attack rate method for routine assessment of the efficacy of pertussis vaccines [30, 92, 93] . This approach has numerous methodologic difficulties and has often given estimates of vaccine efficacy lower than those obtained by other methods (P. E. M. Fine, J. A. Clarkson, and E. Miller, unpublished data). In a recent comparison of methods used to assess the efficacy of mumps vaccine, the highest estimates were obtained with the household secondary-attack rate method [61] . The low estimates of pertussis vaccine efficacy obtained by this method may indicate that challenge dose is more important and immunity less "absolute" in bacterial than in viral infections. There is evidence that immunity to some bacterial infections is dose dependent and can be overwhelmed by a sufficiently large challenge [94]-as, perhaps, during pertussis exposure within the intimacy of the home. Whatever the explanation, the relative simplicity of the household secondaryattack rate method should not be taken as a license for its uncritical application and interpretation.
We are impressed that severallines of evidence indicate that immunity to pertussis -in particular, the immunity derived through vaccination with killed whole-cell vaccines -is neither permanent nor sterile (i.e., protective against infection per se). It is unlike the immunity provided by live-virus vaccines, such as those for measles, mumps, or rubella. Conby guest on April 6, 2011 cid.oxfordjournals.org
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